BioNexus Gene Lab Corp Common stock (BGLC) — Long-term Investment Intensity
BioNexus Gene Lab Corp Common stock (BGLC) has a Long-term Investment Intensity of 3.1% as of September 2025. Long-term investments of $237.76K represent 3.1% of total assets of $7.62 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check BioNexus Gene Lab Corp Common stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
BioNexus Gene Lab Corp Common stock Long-term Investment Intensity (2018–2024)
This chart shows how BioNexus Gene Lab Corp Common stock's Long-term Investment Intensity has evolved across 7 annual periods from 2018 to 2024. As of September 2025, the intensity stands at 3.1%, reflecting long-term investments of $237.76K against total assets of $7.62 Million USD. For the complete balance sheet picture, see how large is BioNexus Gene Lab Corp Common stock's balance sheet.
Annual Long-term Investment Intensity for BioNexus Gene Lab Corp Common stock (2018–2024)
The table below presents the year-by-year Long-term Investment Intensity for BioNexus Gene Lab Corp Common stock from 2018 to 2024, covering 7 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read BGLC total liabilities for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 12.1% | $1.27 Million | $10.43 Million | ▼ -2.8 pp |
| 2023 | 14.9% | $1.70 Million | $11.40 Million | ▲ +1.7 pp |
| 2022 | 13.2% | $1.15 Million | $8.74 Million | ▲ +5.3 pp |
| 2021 | 7.8% | $749.03K | $9.57 Million | ▲ +5.0 pp |
| 2020 | 2.8% | $281.67K | $10.12 Million | ▲ +1.8 pp |
| 2019 | 1.0% | $12.21K | $1.23 Million | ▲ +0.3 pp |
| 2018 | 0.7% | $12.08K | $1.65 Million | — |